PF-6263276

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePF-6263276
Drug Alias NamePF-6263276PF-06263276
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK3Tyrosine-protein kinase JAK1
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumGermany
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A